Transformation Capital Research
Investment Thesis
Transformation Capital is a Boston-based growth equity firm exclusively focused on digital healthcare. Its stated mission is to help entrepreneurs "build a new digital healthcare age...one with simpler, more affordable care." The firm's own language is unambiguous about its focus: "Healthcare is all we do. We think and live in healthcare." Rather than positioning itself as a generalist capital provider, Transformation Capital emphasizes that "access to capital is the easy part" and instead leans on deep healthcare-operator expertise, a network of established healthcare leaders, and strategic introductions ("knowing who's who matters") as its primary differentiators for founders.
Sector Focus
The firm invests exclusively within healthcare, with a portfolio spanning:
- Digital health and virtual care delivery
- Healthcare workforce and staffing technology
- Mental and behavioral health
- Pain management and physical rehabilitation
- Pharmacy benefits and health cost optimization
- Healthcare data, interoperability, and revenue cycle AI
- Value-based care infrastructure and risk contracting
- Medical research and clinical trial infrastructure
- Emergency response technology
AI-enabled healthcare workflows are an increasingly central theme in recent deployments (CodaMetrix, Ketryx, Rad AI, Citizen Health, Qualified Health, Solstice Health).
Stage Focus
Transformation Capital targets growth-stage healthcare companies "seeking to scale transformational solutions," typically Series A/B/C and later growth rounds, once a company has demonstrated a working commercial model and is looking to scale nationally.
Check Size
External sources place the firm's typical check size at roughly $5M-$20M, though the firm has led or co-led rounds up to $60M (Rad AI Series C) at later growth stages, suggesting flexibility to write larger checks for high-conviction follow-ons.
Lead Tendency
Mixed. The firm has led sizeable growth rounds (CodaMetrix's $40M Series B, Ketryx's $39M Series B, Rad AI's $60M Series C) while also participating as a syndicate member in others (Citizen Health's $30M Series A led by 8VC; Arbital Health's $31M Series B led by Valtruis).
Recent Activity
Transformation Capital has been an active investor through 2025 and into 2026:
- March 2024: Led CodaMetrix's $40M Series B for AI-driven medical coding
- January 2025: Led Rad AI's $60M Series C, valuing the company at $525M
- July 2025: Participated in Arbital Health's $31M Series B for value-based care contracting infrastructure
- August 2025: Participated in Citizen Health's $30M Series A for its AI patient advocate platform
- September 2025: Led Ketryx's $39M Series B for AI-based regulatory compliance in life sciences
The firm closed its third flagship fund at an $800M hard cap in 2022, and continues to raise alongside a co-investment vehicle (Transformation Capital Co-Investment Fund III), indicating an actively deploying, well-capitalized posture heading into 2026.
Portfolio Highlights
Transformation Capital's portfolio spans more than 60 healthcare companies across its history, including several unicorns: RapidSOS, Grow Therapy, and Tebra. Other notable names include Sword Health, Datavant, Health Catalyst, DexCare, PlushCare, CareRev, Thriveworks, Unite Us, SmarterDx, Scientist.com, LetsGetChecked, Protenus, Parachute Health, IntelyCare, Ketryx, CodaMetrix, Rad AI, Arbital Health, Citizen Health, and Local Infusion, alongside a wave of newer 2025-2026 additions such as Solstice Health, Qualified Health, Latent, and Alaffia.
Team
- Todd Cozzens, Co-Founder & Managing Partner - 30+ years in healthcare; previously Sequoia Capital, Picis (acquired by UHG), and Marquette Medical Systems (GE); board seats include CodaMetrix.
- Layla Behrouzian, Partner - Former healthcare investment banker at Goldman Sachs, then CareRev; UC Berkeley and Harvard MBA.
- Scott Rosen, Partner - Combines operating and investment expertise across the portfolio; University of Virginia.
- Vinay Shah, Partner & Founding Team Member - Sits on Ketryx's board; part of the firm's original founding team.
- Jared Kesselheim, M.D., Investment Professional - Former Massachusetts General Hospital resident; Harvard College, Harvard Medical School, and Harvard Business School.
The firm also runs dedicated Partner Acceleration and Operations teams that support portfolio companies post-investment, reflecting its "more than capital" positioning.
Decision Process
Not explicitly disclosed. Given the firm's partnership structure and the pattern of named partners taking board seats on portfolio companies, deals appear to move through a multi-partner partnership process typical of growth-stage healthcare investors, rather than a solo-GP or large investment-committee model.
Founder Preferences
Transformation Capital seeks "founders and management teams who understand the current system and see a better way" - i.e., operators with real healthcare-system experience and credibility, not purely technical outsiders. The firm frequently backs founders solving problems they personally experienced within the healthcare system.
Geographic Focus
Primarily United States-based portfolio companies, with the firm headquartered in Boston, MA. No material international/cross-border investment activity was identified.